Circulating serologic and molecular biomarkers in malignant melanoma

Shanique R. Palmer, Lori A. Erickson, Ilia Ichetovkin, Daniel J. Knauer, Svetomir N. Markovic

Research output: Contribution to journalReview article

51 Scopus citations

Abstract

The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90% of deaths from cutaneous malignancies. It remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphologic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.

Original languageEnglish (US)
Pages (from-to)981-990
Number of pages10
JournalMayo Clinic proceedings
Volume86
Issue number10
DOIs
StatePublished - Oct 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Circulating serologic and molecular biomarkers in malignant melanoma'. Together they form a unique fingerprint.

  • Cite this